Q4 22 sales exceeded expectations and both segments contributed healthily, with CA being the dominant growth engine. FPA however was somewhat restrained by external factors. While the 2022 margin is now expected to come in at the upper-end of the guidance, the soft 2023 outlook was maintained. Overall, the Q4 and full-year sales performance was better than that of French peer Vetoquinol. Looking beyond the current macroeconomic uncertainties, we remain confident of Virbac’s long-term business fu ....
20 Jan 2023
2022 ended on a high note but soft 2023 guidance maintained
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2022 ended on a high note but soft 2023 guidance maintained
- Published:
20 Jan 2023 -
Author:
Abhishek Raval -
Pages:
4
Q4 22 sales exceeded expectations and both segments contributed healthily, with CA being the dominant growth engine. FPA however was somewhat restrained by external factors. While the 2022 margin is now expected to come in at the upper-end of the guidance, the soft 2023 outlook was maintained. Overall, the Q4 and full-year sales performance was better than that of French peer Vetoquinol. Looking beyond the current macroeconomic uncertainties, we remain confident of Virbac’s long-term business fu ....